It may benefit the treatment of COVID-19 by the signaling pathways such as advanced glycation end products (AGE)-receptor of AGE (RAGE), TNF, sarcoma-associated herpesvirus infection, IL-17 and human cytomegalovirus infection [41]. There was no statistically significant difference in the incidence of adverse reactions during treatment of other diseases between the LHQW group and the conventional drug group (RR = 0.95, 95% CI = 0.651.39, p = 0.780). The results remained statistically robust after different number supplement of potential studies (for hepatobiliary system damage: RR = 0.90, 95% CI = 0.60 to 1.34; for psychiatric disorders: RR = 1.00, 95% CI = 0.20 to 4.91; for gastrointestinal system damage: RR = 0.86, 95% CI = 0.76 to 0.98; for body as a whole-general disorders: RR = 0.73, 95% CI = 0.212.56). conducted another single center clinical trial which was showed that seven days after treatment with LHQW granules (6g, tid) in conjunction with conventional treatment for COVID-19 patients had a total effective rate of 92.73 % accompanied by significantly reduced major symptoms including fever, cough, fatigue and chest tightness [41]. 367 (6485), 14121413. A recent clinical trial including 36 common cold with wind-heat syndrome patients demonstrated that LHQW (three times daily for four days) treatment could significantly reduce TCM symptom score, with the median time to fever relief of (45) h and the median time to fever clearance of 36h [35]. Therefore, it is essential to perform a systematic review and meta-analysis to assess the effect of Lianhua Qingwen combined with conventional antiviral Western Medicine in clinical treatment of COVID-19 or asymptomatic infection. H. Ohba [Crassulaceae; Rhodiolae Crenulatae Radix et Rhizoma] (85g), Mentha haplocalyx Briq. LHQW group has a reduced incidence of respiratory system damage compared to the conventional drug group (RR = 0.46, 95% CI = 0.290.74, p = 0.001). Here, we performed a meta-analysis of 217 Chinese experimental studies to evaluate the safety of LHQW. Keywords: Chin. [19], Although the medicine has been allowed to be sold in Canada since 2012, Health Canada has cautioned against the use of the Chinese traditional medicine to prevent, treat, and cure COVID-19. Med. Peng L.L., Li L., Shen L., Li X.L. (2015). Five studies reported respiratory system damage as an adverse event. This study was supported by the COVID-19 Pneumonia of Traditional Chinese Medicine Emergency Project, State Administration of Traditional Chinese Medicine of the Peoples Republic of China (2020ZYLCYJ02-1). Meta-Analysis of Efficacy of Oseltamivir and Substitution Therapy for Anti- H1n1 Infection. There are multiple drug trials going on, but there are no specific anti-SARS-CoV-2 drugs or vaccines till now. Clinically, Lianhua Qingwen Capsule can be used in the treatment of cold, flu-induced bronchitis, pneumonia, COPD, interstitial pneumonia and other lung inflammation. Business China. In another prospective multicenter randomized controlled trial in confirmed COVID-19 cases, Hu et al. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D. A novel coronavirus from patients with pneumonia in China, 2019. [Caprifoliaceae; Lonicerae Japonicae Flos], Gypsum Fibrosum, Isatis indigotica Fort. doi:10.1111/j.0006-341x.2000.00455.x, Fan, Z., Guo, G., Che, X., Yang, Y., Liu, Y., Li, L., et al. Data were considered statistically significant at p values <0.05. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. Keywords: Lianhua Qingwen, adverse reaction, COVID-19, influenza, traditional Chinese medicine, meta-analysis, Citation: Hu C, He B, Gong F, Liang M, Zhao D and Zhang G (2022) The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis. 1 Lv R.B., Wang W.J., Li X. Res. Introduction As the global epidemic continues to spread, countries have tapped effective drugs to treat new coronavirus pneumonia. Subgroup analysis showed a lower level of nausea or vomiting in LHQW group (RR = 0.60, 95% CI = 0.480.74, p < 0.001), no statistical difference was detected for other symptoms of gastrointestinal system damage. (japanese honeysuckle) flower 27.41 mg, gypsu . (2020). Zhou X.P. Study supervision and funding were done by GZ. [9], During the COVID-19 pandemic, the government of the People's Republic of China (PRC) approved the use of Lianhua Qingwen for mild to moderate COVID-19 cases in January 2020, and promotes the use of the medicine abroad. doi:10.1016/j.jep.2013.12.022. Careers, Unable to load your collection due to an error. Exploring material basis and mechanism of Lianhua Qingwen prescription against coronavirus based on network pharmacology. LHQW had been proven to accelerate the improvement of acute exacerbation of COPD (AECOPD) patients, especially for the high-risk subgroup, due to the decreased release of inflammatory mediators including IL-8, TNF- , IL-17, and IL-23 [38]. J. Med. [11] The pro-establishment DAB alliance was found to have distributed unregistered doses of LHQW, in breach of health regulations. Efficacy of Lianhua Qingwen Compared With Conventional Drugs in the Treatment of Common Pneumonia and Covid-19 Pneumonia: a Meta-Analysis. Subgroup analysis revealed that LHQW group has a reduced incidence of rash than the conventional drug group (RR = 0.58, 95% CI = 0.390.86, p = 0.007), no statistical difference was detected for itchy skin. Pharmacol. Lianhua Qingwen capsule/granule (LHQW) is obtained by combining Ma Xing Shigan Decoction with Yinqiao Powder and widely used in the clinical treatment of respiratory disorders (Liu et al., 2010). Vahl [Oleaceae; Forsythiae Fructus] (255g), Lonicera japonica Thunb. Heterogeneity was evaluated using I2 statistic. The most common adverse reactions in our analysis were gastrointestinal system damage, skin and its appendage damage. Lianhua Qingwen Capsules/granules Product Details. Due to the inclusion of Ephedra people with high blood pressure, anxiety, history of seizures, irregular heart beats, or other heart heart conditions, should avoid taking Linhua Quingwen. Adv. Upon full text filtering of the remaining 715 citations, 498 were excluded due to a number of reasons (shown in Figure 1). 6 (01), 6364. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. We observed no significant alteration in the security evaluation indexes of treatment among different diseases. System-Organ Code Retrieval Involved. LHQW: Lianhua Qingwen. Effects of Four Types of Integrated Chinese and Western Medicines for the Treatment of Covid-19 in china: a Network Meta-Analysis. (2015). 7 (3), 177188. (Guanghuoxiang), Rheum palmatum L. (Dahuang), Rhodiola rosea Linn. Twenty-three studies on other diseases were included, with 12 reporting adverse reactions. Furthermore, they identified two important metabolites, prostaglandin F2 and arachidonic acid, and their arachidonic acid metabolism pathway, as vital indicators of LHQW in treating influenza by using serum metabolomics analysis [19]. These in vivo data further demonstrate the antiviral effects of LHQW as well as its lung protection role. Nevertheless, pressing researches should be conducted to illuminate the unconfirmed effects, regulatory mechanisms and adverse reactions of LHQW in treating COVID-19. Contraindications . Li H.R., Chang L.P., Wei C., Jia Z.H. Patients with severe cases will develop acute respiratory distress syndrome and septic shock, and eventually develop multi-organ failure and death [5]. However, both groups did not differ in the rate of conversion to severe cases or viral assay findings. In the Philippines, its Food and Drug Administration approved Lianhua Qingwen on 7 August 2020 as a traditional herbal product that helps remove "heat-toxin invasion of the lungs, including symptoms such as fever, aversion to cold, muscle soreness, stuffy and runny nose". Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Chinese Pharmacopoeia (2020). BMJ. We aim to assess the efficacy and safety of Lianhua Qingwen combined with Conventional antiviral Western Medicine in Clinical treatment of COVID-19 or asymptomatic infection. Evid. Creative Commons Attribution License (CC BY). [4] Its formulation includes 13 herbs which are said to have been used for medical purposes as early as the Han dynasty. Currently, the drug has been approved for marketing in 23 countries and regions, including Canada, Russia, Cambodia and Indonesia. N. Engl. Ther. No proven effective antiviral treatments for COVID-19 pneumonia are available at present (Ahsan et al., 2020; Cao et al., 2020; Chan et al., 2020; Khan et al., 2020; Kupferschmidt and Cohen, 2020). The Plant List (2021). Significant heterogeneity was detected for COVID-19 pneumonia (I2 = 76.0), hand-foot-mouth disease (I2 = 62.1), rheum (I2 = 88.2), and drowsiness of nervous system damage (I2 = 91.8). However, no consensus has been reached on the security of LHQW to date. Li L.C., Kan L.D. School of Pharmacy, Faculty of Life Sciences, University College London, United Kingdom. Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. the contents by NLM or the National Institutes of Health. Meta-analysis in Clinical Trials. Data analysis were done by CH and DZ. Assoc. Yu P., Li Y.Z., Wan S.B., Wang Y. Efficacy of Lianhua Qingwen granules combined with abidor in the treatment of mild COVID-19. Traditional Chinese medicine treatment maintains homeostasis through interactions between the body and pathogens or establishing a balance between stimulating antiviral responses and suppressing overactive immune responses that leads to tissue damage (Shi et al., 2021). In vitro, LHQW capsules could inhibit the proliferation of influenza viruses of various strain with the 50 % inhibitory concentration ranging from 0.35 to 2mg/mL [24]. Clin. There was no statistically significant difference in the incidence of adverse reactions during treatment of chronic obstructive pulmonary disease between the LHQW group and the conventional drug group (RR = 1.27, 95% CI = 0.513.17, p = 0.608). [15], In the Philippines, its Food and Drug Administration approved Lianhua Qingwen on 7 August 2020 as a traditional herbal product that helps remove "heat-toxin invasion of the lungs, including symptoms such as fever, aversion to cold, muscle soreness, stuffy and runny nose". With gradual improvement of the adverse drug reaction monitoring system of China, reports of adverse reactions or events have increased. Lianhua Qingwen combined with conventional treatment obviously improved COVID-19. All authors approved the final version of this manuscript. Lianhua Qingwen Jiaonang with Chinese Characters; As per continuing post-marketing surveillance, there is still incessant sale and distribution even through social media platforms, such as Facebook, of Lianhua Qingwen Jiaonang with Chinese characters, which were verified as unregistered by the FDA. Traditional Chinese medicine Lianhua Qingwen capsule has been proven effective for the treatment of COVID-19, China's top respiratory expert Zhong Nanshan said in a webinar with overseas Chinese students on Monday. Dr. Tan says that LianHua QingWen is not advisable for COVID patients who are experiencing a chilling sensation due to the infection. Overall, 61 chemical compounds of LHQW (including iridoids, flavonoids, anthraquinones, phenylpropanoids, triterpenoids, and other types) have been unambiguously or tentatively identified via rapid ultra-performance liquid chromatography coupled with diode-array detector and quadrupole time-of-flight mass spectrometry (Jia et al., 2015). The Trim and Fill method was further applied to assess the impact of publication bias. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Wang X., Ding Y.Q. The control and improvement of the present COVID-19 situation in China could not be separated from the extensive participation of TCM, which has been proven effective by the clinical studies in COVID-19 patients [41,44,48,49]. J. Intern. Six studies were included on treatment of herpes zoster and reported the adverse reactions. Secondly, separate evaluations were further performed for different diseases and types of adverse reactions. An outbreak of Coronavirus Disease 2019 (COVID-19) which was infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still spreading and has led to unprecedented health emergency over the world. Five studies reported heart rate and arrhythmia as adverse events. 12, 640782. doi:10.3389/fphar.2021.640782. [3], Lianhua Qingwen was developed by Shijiazhuang Yiling Pharmaceutical in 2003 as a treatment for severe acute respiratory syndrome (SARS) following the outbreak of the disease in 2002 and was listed by the National Health Commission of China in 2004 as a treatment for influenza and other respiratory disease. Meanwhile, the network pharmacology analysis confirmed that its effects were mainly focused on the biological processes such as the response to LPS, the molecular response to bacterial origin, the response to metal ions and cell biological stimulation [41]. Tian S., Song X., Wang Y., Wang X., Mou Y., Chen Q., Zhao H., Ma K., Wu Z., Yu H., Han X., Wang H., Wang S., Ji X., Zhang Y. Chinese herbal medicine Baoyuan Jiedu decoction inhibits the accumulation of myeloid derived suppressor cells in pre-metastatic niche of lung via TGF-/CCL9 pathway. 160, 105101. doi:10.1016/j.phrs.2020.105101, Xiao, M., Tian, J., Zhou, Y., Xu, X., Min, X., Lv, Y., et al. Subgroup analysis additionally demonstrated LHQW group has a reduced incidence of rash, nausea or vomiting, and resurgence of disease. HHS Vulnerability Disclosure, Help Among the 13 included studies on treatment of hand-foot-mouth disease, eight reported adverse reactions. The mechanisms were mainly involved the antiviral activity, and regulation of inflammation response as well as immune function. Vahl [Oleaceae; Forsythiae Fructus], Lonicera japonica Thunb. doi:10.11954/ytctyy.201608076, Chan, K. W., Wong, V. T., and Tang, S. C. W. (2020). Although the results obtained for influenza were consistent with our findings, the control group in this earlier study was treated with a single drug while our control groups were treated with antiviral drugs, conventional antibiotics or symptomatic therapy. Few reports of adverse reactions in the course of treating COVID-19 pneumonia with LHQW are available. Lianhua Qingwen Capsules has a better therapeutic effect on viral influenza, but the incidence of adverse reactions is high, and its safety must be taken seriously. Lian Hua Qing Wen capsules (LHQW) is the most effective and commonly-used clinical formula in treating respiratory infection for thousands of years in China. Ding Y., Zeng L., Li R., Chen Q., Zhou B., Chen Q., Cheng P.L., Yutao W., Zheng J., Yang Z., Zhang F. The Chinese prescription Lianhua Qingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. The search keywords for screening the literature information were virus, COVID-19, or SARS-CoV-2, and Lianhua Qingwen. Hence, the researches on specific active components of LHQW are still important and the reduction of irrelevant ingredients may be related to less adverse reactions. In addition to western medicine, the potential adverse drug reactions (ADRs) can not be ignored. LQ15H280003), the Clinical Research Projects of Zhejiang Medical Association (No. This review provides comprehensive evidence of LHQW as a complementary strategy for treating COVID-19. Liu, X. Y. In the COVID-19 pneumonia epidemic of China, traditional Chinese medicine plays a critical role in preventing mild or ordinary COVID-19 patients from developing into serious or critical patients (China Central Television News, 2020). Med. First, the data indicated that LHQW combined with conventional therapies could markedly improve the clinical symptoms, quality of life and absorption of lung infiltration during anti-viral therapy, but the level of evidence is weak due to the included small sample trial and lacking the classification of disease severity. (Nat. Nervous system damage was described as an adverse event in 34 studies. Efficacy and Safety of Lianhuaqingwen for Mild or Moderate Coronavirus Disease 2019. Shi, M., Peng, B., Li, A., Li, Z., Song, P., Li, J., et al. doi:10.14009/j.issn.1672-2124.2013.08.001, Wang, Y. In a lipopolysaccharide (LPS)-induced acute lung injury animal model, LHQW could efficiently decrease the chemotaxis of monocytes toward the pulmonary infection foci, and thus blocked the disease development by down-regulating MCP-1 expression [33]. A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components. However, in evaluation of security index, Eggers test and funnel plot analyses disclosed the existence of publication bias with regard to hepatobiliary system damage, psychiatric disorders, gastrointestinal system damage and body as a whole-general disorders. Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Cheng D.Z., Wang W.J., Li Y., Wu X.D., Zhou B., Song Q.Y. In mice after infected with the flu virus FM1, LHQW capsule obviously increased IFN- content in lung homogenate and significantly reduced the levels of TNF-, IL-1 and IL-6 in lung tissues, and had inhibiting effect on the marked decrease of CD4+ and CD4+/CD8+ [31,32]. Ma Y., Zhang Z., Wei L., He S., Deng X., Ji A., Zhou B., Jiang D., Li M., Wang Y. Efficacy and safety of Reduqing granules in the treatment of common cold with wind-heat syndrome: a randomized, double-blind, double-dummy, positive-controlled trial. Though the quality of the included literature was mixed, the lung protection effects of LHQW was demonstrated. Evid. The duration of sputum was shorter in the Lianhua Qingwen group than in the conventional drug group (WMD = 1.10, 95% CI = 1.50 to 0.70, < 0.001). 132 studies documented gastrointestinal system damage. Med. Liu Y., Liu L., Cao M.M., Wen J., Zhou S., Jiang H., Zhang Y., Zhao R.S., Yang Y.H. Notably, the stomach is full after a meal, and LHQW does not directly contact the gastric mucosa, which reduces the risk of irritation of stomach mucous membrane and thus the occurrence of side-effects. The latest meta-analysis by Fan et al. Inhibitorv Effect of Lianhua Oingwen Water Extract on Methicillin-Resistant staphylococcus Aureus Biofilm In Vitro. Recent study then showed that the main components of LHQW included chlorogenic acid, caffeic acid, isochlorogenic acid B, isochlorogenic acid C, phillyrin, forsythiaside A, and rutin by high performance liquid chromatography (HPLC) analysis [19]. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. Though no specific drug has been developed so far, emerging agents have been confirmed effective or potentially beneficial to restrain it. LYY19H280006, No. Pharmacol. Z., Wang, H. T., Han, X., Liu, C., Sun, Y. N., Liu, B., et al. (Jinyinhua), Ephedra sinica Stapf (Mahuang), Armeniacae Amarum Semen (Kuxingren), Gypsum Fibrosuum (Shigao), Isatis tinctoria L. (Banlangen), Dryopteridis Crassirhizomatis Rhizoma (Mianmaguanzhong), Houttuynia cordata Thunb. 37 studies reported adverse reactions of skin and its appendage damage. Our findings support the adverse reactions recorded by Yiling Pharmaceutical, and compare the incidence risk of gastrointestinal system damage and rash with the control group. LHQW is one of the TCM formulations that have been officially approved to treat COVID-19 patients, which may be due to its antiviral, lung protection, and regulation of inflammation response as well as immune regulation actions (Fig. 2015, 731765. doi:10.1155/2015/731765, Jin, L., Xu, Y., and Yuan, H. (2020). LHQW also decreased the influenza viral titers in the lungs of mice, with decreased inflammatory cytokine levels in the early stages of infection [24]. government site. Accessibility 37 (6), 25752579. "It's the first time in the world that we have enough evidence to prove Lianhua Qingwen capsule is effective and can help . (2015). Most patients infected with the coronavirus are showing mild symptoms, taking Lianhua Qingwen Capsule as early as possible, the effect will be obvious, It [sic] can recover 91.5% of mild cases and . Yang C.X., Qu J., Liu Y.T., Meng S.W., Wang B.L., Feng M.Q., Sun Y. The documents were filtered and summarized for final evaluation. Academician Yiling Wu systematically constructs the theory of collateral disease, provides theoretical guidance for the formulation of Lianhua Qingwen, and gives . Otherwise, the fixed-effects model was used (DerSimonian and Laird, 1986; Higgins et al., 2003). This work was supported by the National Natural Science Foundation of China (No. During the study, no serious adverse events were reported. The complex components of LHQW stand for multiple targets and pleiotropic effects, but may also lead to more ADRs. Since the adverse reactions of LHQW are relatively minor, these functional changes can be recovered. Study on the network pharmacology and evidences of Lianhua Qingwen in the treatment of Novel Coronavirus (2019 nCoV) Pneumonia. Meta-analysis and systematic review of efficacy and safety of Lianhua Qingwen in adjuvant treatment of adult pneumonia. J. Eval. Wang, Y., Greenhalgh, T., and Wardle, J. Cheng D.Z., Li Y. Results: In total, 217 experimental studies were included. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). Beijing: China Medical Science Press. Drafting of the manuscript was done by CH and BH. Effect of Maxing Shigan Tang on H1N1 influenza A virus-associated acute lung injury in mice. ACE2, angiotensin-converting enzyme 2; ADRs, adverse drug reactions; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; AGE, advanced glycation end products; ALI, acute lung injury; COPD, chronic obstructive pulmonary disease; COVID-19, Coronavirus Disease 19; EC50, median effective concentrations; HPLC, high performance liquid chromatography; IBV, influenza B virus; IFN, interferon; IL, interleukin; LHQW, Lianhua Qingwen; LPS, lipopolysaccharide; IP, interferon-inducible protein; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; NF-B, nuclear factor-kappa B; RAGE, receptor of advanced glycation end products; SARS, Severe Acute Respiratory Syndrome; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; TCM, traditional Chinese medicine; UPLC-DAD-QTOF-MS, ultraperformance liquid chromatography coupled with diode-array detector and quadrupole time-of-flight mass spectrometry, Coronavirus, SARS-CoV-2, Lianhua Qingwen, Antiviral activity, Complementary strategy, {"type":"clinical-trial","attrs":{"text":"NCT02867358","term_id":"NCT02867358"}}. doi:10.3969/j.issn.1672-2809.2020.13.020, Liu, C. Y., Li, X. Q., and Cai, S. Q. This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of COVID-19. Research progress in use of traditional Chinese medicine for treatment of spinal cord injury. It was demonstrated that the use of LHQW also brought the incidence of gastrointestinal reactions, as well as skin and its accessories injuries, including diarrhea, abdominal distension, gastrointestinal discomfort, rash, and itching, despite the low quality of the included documents [50,51]. The discovery of potential effective drugs on the market becomes one of the principal means to develop antiviral drugs for COVID-19. It is not registered as a COVID-19 medication, and a doctor's prescription is required for its use. Lianhua Qingwen(Forsythiae fructus 225 mg, Lonicerae japonicae flos 225 mg, Ephedrae herba (processed w/ honey) 85 mg, Armeniacae semen amarum (stir-baked) . [12], In April 2022, the Financial Times reported that the leading COVID-19 health official in the PRC, the famous epidemiologist and pulmonologist Zhong Nanshan - who has also been the most prominent scientific promoter of Lianhua Qingwen - had undisclosed prior investments in large stakeholdings in corporations producing Lianhua Qingwen and other treatments under question. COVID-19 has led to a great case fatality. [Cruciferae; Isatudus Radix] (255g), Dryopteris crassirhizoma Nakai [Polypodiaceae; Dryopteris Crassirhizomatis Rhizoma] (255g), Houttuynia cordata Thunb. Li X., Yang Y., Liu L., Yang X., Zhao X., Li Y., Ge Y., Shi Y., Lv P., Zhang J., Bai T., Zhou H., Luo P., Huang S. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019. 152 (3), 393402. Efficacy and Safety of Lianhua Qingwen Granule Combined with Oseltamivir in the Treatment of Influenza Virus Infection in Children. Nevertheless, there are also potential limitations that need to be improved for future challenges. Dang Y., Xu J., Yang Y., Li C., Zhang Q., Zhou W., Zhang L., Ji G. Ling-gui-zhu-gan decoction alleviates hepatic steatosis through SOCS2 modification by N6-methyladenosine. Subgroup analysis additionally revealed a reduced incidence of some adverse reactions in the LHQW group compared to the conventional drug group (Rash of skin and its appendage damage, dizziness or headache owing to nervous system damage, nausea or vomiting from gastrointestinal system damage and resurgence of disease from other adverse reactions). The recent meta analysis reported 22 studies with a total of 2,007 patients, showing that the adjuvant therapy of LHQW with western medicine could improve the clinical efficiency and C-reactive protein index, shorten the time of antifebrile, cough time, rhondros duration and imaging time, as well as speed up the recovery of pneumonia patients [39]. Warning 1. Besides, on April 14, 2020, the National Medical Products Administration of China approved modifying the specification of LHQW (Yiling Pharmaceutical Inc.) by adding a new indication for COVID-19 treatment in mild and normal cases. Finally, our data showed that LHQW reduces the incidence of a number of adverse reactions compared with conventional drugs. The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author. ). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Asia-Pacific Traditional Med. Pharmacol. Despite the ban, Lianhua Qingwen has been sold illegally in Australia as a COVID-19 treatment.[21]. Recent advances have discovered that COVID-19 is a systematic disease targeting the lungs, vasculatures, and immune system, and involves severe lung inflammation and immune deficiency in terms of cytokine storm, neutrophil extracellular traps, as well as imbalance of lymphocyte subsets and so forth [[4], [5], [6]]. Zhong Y., Zhou J., Liang N., Liu B., Lu R., He Y., Liang C., Wu J., Zhou Y., Hu M., Zhou J. Combined with western medicine conventional therapy in the treatment of 63 suspected cases of Coronavirus Disease 2019. Lianhua Qingwen capsules have been proven to speed up symptoms recovery but no effect in preventing infections from worsening. Front. Liu-Cheng Li was responsible for drafting the manuscript. 13:764774. doi: 10.3389/fphar.2022.764774. Wang F.C., Shen B.X., He C.Y., Zhao W.C., Nie S.L. Available at: http://www.theplantlist.org/(Accessed December 18, 2021). Treatment of SARS-Cov-2: How Far Have We Reached? Literature analysis of clinical application and adverse drug reaction/event of Lianhua Qingwen capsule. Front. Homogeneity of baseline data was reported in most studies. 81503129, No. (2020). Alternat Med. These above ingredients are decocted, distilled, filtered, refrigerated, mixed well with powdered sugar, dextrin or starch, dried and finally made into LHQW (Chinese Pharmacopoeia, 2020). The quantitative analysis of all eligible studies. J. Chin. The site is secure. The main characteristics of the eligible studies are summarized in Supplementary Table S1, while the composition of LHQW and how LHQW were reported in the original studies presented in Supplementary Table S2.
lianhua qingwen contraindication